GNTA
$0.80
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Intraday
Recent News
European Equities Traded in the US as American Depositary Receipts Higher Tuesday
European equities traded in the US as American depositary receipts were rising Tuesday morning, up 1
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business
Genenta Science SPA (NASDAQ:GNTA) is among the best Italian stocks to buy in 2026. Genenta Science SPA (NASDAQ:GNTA) will hold an extraordinary shareholders meeting on March 26. This comes on the back of the company announcing a major shift in its business strategy. Genenta Science, which has all along been concentrating on biotech programs with […]
European Equities Traded in the US as American Depositary Receipts Gain Friday
European equities traded in the US as American depositary receipts were rising on Friday morning, up
US-China Trade Optimism Lifts US Equity Futures Pre-Bell
US equity futures were up ahead of Monday's opening bell as traders monitored developments surroundi
Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism
Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology. This move highlights growing confidence in Genenta’s research trajectory. See our latest analysis for Genenta Science. Genenta Science's share price soared this week following the expanded Anemocyte collaboration, locking in a remarkable 1-day share price return of 91.95% and a 7-day return...